Impact Biomedical Inc.
IBO- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001834105
In the last 90 days, Impact Biomedical Inc. insiders filed 0 open-market purchases and 1 sale; 23 institutions reported holding it in 13F filings for Q2 2026, worth $1.76M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Impact Biomedical Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 0 | 10 | +10 |
| Shares | 0 | 66.0K | +66.0K |
| Value | $0 | $59.3K | +$59.3K |
New holders (10)
Institutions that held Impact Biomedical Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 13,361 | $26.7K | 0.00% |
| HRT Financial LP | 12,502 | $25.0K | 0.00% |
| Bank of America Corp | 2,596 | $5.19K | 0.00% |
| Barclays PLC | 1,120 | $2.24K | 0.00% |
| Morgan Stanley | 58 | $116 | 0.00% |
| Wells Fargo & Company | 29 | $58 | 0.00% |
| Danske Bank A/S | 3 | $6 | 0.00% |
| UBS Group AG | 3 | $6 | 0.00% |
| Group One Trading, L.P. | 1 | $2 | 0.00% |
| Ferguson Wellman Capital Management, Inc | 36,364 | $0 | 0.00% |
Sold out (0)
Institutions that held Impact Biomedical Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
None.